The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive breast cancer – the most common form of breast cancer in Australia – according to preclinical studies led by Walter and Eliza Hall Institute researchers.
Ook interessant voor je
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
